As Pharma Regulation Tightens, the Moat Around Regulatory Translation Deepens

In 2024, the global pharmaceutical regulatory environment continues to evolve: the EU Clinical Trials Regulation (CTR) is in full application, IDMP data-submission requirements are landing progressively, and national regulators update filing requirements frequently. Every step of a pharma company's internationalization brings large volumes of regulatory document translation — and the "zero-tolerance" nature of this work stands out even more in the AI era.

What makes regulatory submission translation special: it is not just language conversion but a compliance act. Dosage statements, adverse-reaction descriptions and the presentation of statistical data in filing documents must strictly follow the target regulator's technical norms; a single terminology deviation can invite regulatory queries or even rejection. Such translation has long been performed by professional linguists with pharmacy or medical backgrounds, backed by dual review and enforced term-base validation.

AI adoption in this field is advancing too, but along a clear and restrained path: machine translation serves internal reference and literature research, formal submissions remain primarily human-translated, and AI plays auxiliary roles such as terminology consistency checking. Regulators' accountability mechanisms for filing quality ensure the "a human answers for the result" structure will not change.

For pharmaceutical companies, the criteria for choosing a regulatory translation partner have never changed: professional background, quality system, traceable process. In the AI era, these criteria are not outdated — they matter more.